tickrz reports
  
tickrz rank
C
Johnson & Johnson (JNJ)
Healthcare | Drug Manufacturers - Major
CEO: Alex Gorsky
Employees: 127100
jnj.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank338Dividend Rank60
Moat Rank36Financial Strength Rank11
Growth Rank212Momentum Rank300
DIVIDEND ANALYSIS
Dividend Yield2.52%
Payout Ratio52.85%
3 yr Dividend Growth6.74%
VALUATION RATIOS
P/E Ratio21.19x
P/B Ratio4.97x
P/S Ratio4.85x
EV/EBITDA Ratio14.15x
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity46%
Interest Coverage26.56x
MOAT
ROE23.09%
ROIC28.62%
Net Margin22.99%
GROWTH
5 yr EPS Growth11.18%
5 yr SPS Growth2.04%
5 yr BPS Growth4.43%
Johnson & Johnson has carved out a durable competitive advantage within its industry
 tickrz summary
Johnson & Johnson receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Johnson & Johnson's valuation score is comprised of a P/E ratio of 21.2x, a P/B ratio of 5x, a P/S ratio of 4.9x, and an EV/EBITDA ratio of 14.2x. Johnson & Johnson ranks 338 out of the S&P 500 constituents on valuation--a relatively weak score.Johnson & Johnson ranks 61 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Johnson & Johnson warrants further investigation.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Johnson & Johnson appears to have a durable competitive advantage within the Healthcare sector. Johnson & Johnson has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 26.56x, a debt/equity ratio of 46% and a Moat Rank of 36 translate to a strong Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 7.55% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 300. Based on its 12 month stock performance, Johnson & Johnson will not appeal to momentum investors.

 yield
 value + yield
Shares currently yield 2.52%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Johnson & Johnson ranks 60 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will want to closely investigate Johnson & Johnson.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 11.2% 5 year annualized EPS growth, 2% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 4.4% combine to produce this average score.

Johnson & Johnson (JNJ)
Healthcare | Drug Manufacturers - Major
CEO: Alex Gorsky
Employees: 127100
jnj.com


tickrz rank
C

VALUATION RATIOS
P/E Ratio21.19x
P/B Ratio4.97x
P/S Ratio4.85x
EV/EBITDA Ratio14.15x
DIVIDEND ANALYSIS
Dividend Yield2.52%
Payout Ratio52.85%
3 yr Dividend Growth6.74%
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity46%
Interest Coverage26.56x
MOAT
ROE23.09%
ROIC28.62%
Net Margin22.99%
GROWTH
5 yr EPS Growth11.18%
5 yr SPS Growth2.04%
5 yr BPS Growth4.43%

TICKRZ RANK
Johnson & Johnson receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Johnson & Johnson's valuation score is comprised of a P/E ratio of 21.2x, a P/B ratio of 5x, a P/S ratio of 4.9x, and an EV/EBITDA ratio of 14.2x. Johnson & Johnson ranks 338 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Johnson & Johnson ranks 61 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Johnson & Johnson warrants further investigation.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Johnson & Johnson appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Johnson & Johnson has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 26.56x, a debt/equity ratio of 46% and a Moat Rank of 36 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 7.55% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 300. Based on its 12 month stock performance, Johnson & Johnson will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 2.52%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Johnson & Johnson ranks 60 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will want to closely investigate Johnson & Johnson.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 11.2% 5 year annualized EPS growth, 2% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 4.4% combine to produce this average score.